Breaking Now



Cyprotex PLC
11 November 2003



Press Release 11 November 2003



Cyprotex reports successful customer validation studies for CloeTM Technology



Cyprotex (LSE: CRX) today announces results of successful trials of its Cloe PK
TM software applied to over 150 potential drugs provided by seven pharmaceutical
companies. The trials showed that Cloe PKTM can estimate how long a drug stays
in the body and is sufficiently accurate to be used in the rapid selection of
promising compounds and the early elimination of those likely to fail.



In parallel, blind trials of the Cloe ScreenTM experimental testing technology
on several hundred compounds provided by six laboratories from major
pharmaceutical companies, all demonstrated a high degree of accuracy.



The CloeTM technology can be used to predict what would happen in humans as well
as in rats, one of the main species used in pharmaceutical research, and the
cumulated data showed that the CloeTM technology allowed the estimation of human
outcomes more accurately than experiments carried out in live rats. These
results demonstrate that customers can confidently use the CloeTM technology to
reduce the number of animals they use in drug discovery research, while
improving the chance that their drug would work in humans.



The detailed results of the trials were described to leading industry and
academic practitioners in the field of computer-based prediction for drug
discovery, who recently visited Cyprotex's laboratories in Macclesfield. The
event was a satellite meeting of the UK QSAR (see below) Discussion Group
meeting, a twice-yearly event which allows industry and academic scientists to
exchange information on progress in the development of computer-based predictive
approaches, which was also hosted by Cyprotex.



Dr David Leahy, Chief Scientific Officer and Founder of Cyprotex plc, said: 'I
am proud of the way that our skilled team of scientists and engineers have
delivered, in less than 18 months, uniquely accurate and cost-effective
technology for the estimation of pharmacokinetics.



'We now have the evidence that demonstrates to potential partners that the Cloe
TM technology can improve productivity in drug discovery. We are able to offer
to our partners similar information to that obtained in a Phase One clinical
trial on every compound they synthesise, at a fraction of the cost, within days
rather than years.'



The acronym QSAR stands for Quantitative Structure-Activity Relationships and
refers to mathematical or statistical relationships between the chemical
structure of a drug and its properties.

- Ends -



Media enquiries:
Bankside
Henry Harrison-Topham / Heather Salmond Tel: +44 (0) 20 7444 4140
heather.salmond@bankside.com www.bankside.com


Notes to editors:

Cyprotex PLC

Cyprotex is a specialist provider of pharmacokinetic information and technology
to evaluate and optimise key properties of potential drugs that determine how
well they will be absorbed, distributed, metabolised and excreted by the body.
This provides pharmaceutical partners with a sound basis for decision-making
regarding compound selection and design that takes into account how the compound
will behave in the body. Cyprotex predicts the likely outcome of administering
either orally or intravenously administered compounds by modelling human and rat
physiology. Predictions require basic compound information that can be derived
in the laboratory using established methods, all of which are routinely
performed by Cyprotex's experimental capability. This unique combination of
technologies is aimed at improving pharmaceutical productivity by improving the
quality of compound libraries and drug candidates progressing through the drug
pipeline. Cyprotex is based in the UK and is listed on the Alternative
Investment Market of the London Stock Exchange (CRX).


This information is provided by RNS
The company news service from the London Stock Exchange

Great news & the orders should start to flood in!

Cyprotex share price surged 18.52% on friday ahead of Finals out on Monday. Strong RSI, MACD Buy signals generated. DYOR as open on Monday could see the share price take off vertical especially if there is more contract news announced with results!

Finals show a significant improvement as expected.

Cyprotex PLC
19 April 2004

Press Release 19 April 2004


Cyprotex PLC

('Cyprotex' or 'the Company')

Preliminary Results for year ended 31 December 2003


Cyprotex PLC, a drug discovery technology and information company, today reports
its preliminary results for the year ended 31 December 2003.

Highlights

• Turnover increased 62% to 1.05 million (For previous 14 months
period 0.65 million)
• Pre-tax loss decreased 42% to 2.05 million (For previous 14 month
period 3.51 million)
• 0.8 million raised by issue of 4.5 million New Ordinary Shares
• Post year-end placing raised 2.94 million (net of expenses)
• Agreements signed with AstraZeneca, ALTANA, Roche, and Solvay

Commenting on the results, Robert Morrisson Atwater, Chairman and Chief
Executive Officer of Cyprotex PLC, said:

'At the beginning of the new financial year we effected a successful Placing
which has provided capital that will be used to accelerate our marketing and
sales activities in relation to our Cloe range of products as well as fund the
acquisition of new equipment and employment of new personnel to deal with the
anticipated growth in turnover.

'This year Cyprotex has delivered on a total of 24 revenue generating contracts
with 17 companies and we expect further contracts to be delivered in the near
future. We have demonstrated the effectiveness of our technology, having
received validation from major biotech and pharmaceutical companies that we can
deliver high quality products effectively to customers. We look forward to a
successful year.'



For further information, please contact:
Cyprotex PLC
Robert Atwater, Chairman & Chief Executive Officer Tel: +44 (0) 1625 505 100
rmatwater@cyprotex.com www.cyprotex.com
Media enquiries:
Bankside
Henry Harrison-Topham / Heather Salmond Tel: +44 (0) 20 7444 4140
heather.salmond@bankside.com www.bankside.com


Chairman and Chief Executive's Statement

Financial Summary

Turnover for the year ended 31 December 2003 was 1,052,953. In the 14 months
ended 31 December 2002, turnover totalled 647,770. Gross profit for the year
was 803,101 after deducting cost of sales. For the 14 months period to 31
December 2002, the gross profit was 584,934. Pre-tax losses for the year
amounted to 2,049,401, and after a taxation credit of 189,256 the loss for the
year totalled 1,860,145. The loss per share was 2.05p and no dividend is being
paid.

At the end of December 2003, the Group's cash position was 491,230, but since
then a placing was carried out that raised 2.94 million net of expenses. This
provision of further working capital enables the Group to fund the increased
marketing and sales of its Cloe ScreenTM and Cloe PK(TM) technology and acquire
new equipment and additional personnel to meet the anticipated growth in
turnover.



Product Development

Significant progress was made during the year with the development and
successful launch of our Cloe range of products to support drug discovery. Cloe
ScreenTM is an industrial scale system that produces high quality data on the
absorption, distribution, metabolism and excretion (ADME) properties of
compounds at a fraction of the costs of current methods. Cloe PK(TM) is a novel
system that helps our partners interpret ADME data using a model of a 'virtual'
human or rat to predict the time course of potential drugs in the body. These
technologies can be used effectively in combination to help our partners to
prioritise the best compounds to progress through the discovery and development
process, and to improve the design of new compounds. We are successfully
leveraging Cloe PK(TM) into our sales and we believe that similar integrated
Cloe offerings will generate further new business.

We have already reached the finalisation stage of long-term contracts for our
Cloe-based products with two of the world's largest pharmaceutical companies,
and high-level discussions are continuing with other pharmaceutical and biotech
majors.

Customer Development

Having serviced a total of 24 contracts with 17 global pharmaceutical and
biotech companies in 2003, our portfolio of customers for drug discovery support
services has been further enhanced since the end of the year. Agreements to
provide drug discovery support have been signed with Avidex, ALTANA, Roche,
AstraZeneca, and Solvay that once again demonstrates the value and effectiveness
of our technology.



Board changes

In August 2003, I was appointed Chairman and Chief Executive and since the start
of the current year a number of strategic changes to the Board have been made.
In January 2004, Dr. Martial Lacroix, a Vice President of Montreal-based venture
capital group, Genechem Inc. and Mr Minhaz Manji, the Managing Director of
Monteacute House Limited joined the Board as non-executive Directors.

The Company will benefit greatly from the expertise of these two new directors.
As a result of the continuing development of the Group and these new
appointments, the previous non-executive Directors agreed to relinquish their
Board appointments.

John Nicholson, formerly a Director and Chief Operating Officer of the Company
resigned, along with non-executive directors Dr Colin Picton and Dr Rosemary
Drake. The Board would like to take this opportunity to thank them for their
assistance in the development of the Company and we wish them well for the
future.



Simcyp

The litigation between the Company and the University of Sheffield over disputed
copyright has been dismissed by the Court of Appeal and has since been resolved
amicably. The disputed copyright has not been used nor is it intended to be
used commercially, and the Company long ago ensured that no part of its business
activities or plans was dependent on ownership or licensing of the copyright.
The Company has made sufficient provision in past accounts to cover any costs
that are payable.



Share Option Scheme

The Company is proposing to amend the Rules of the Unapproved Discretionary
Share Option Scheme (the 'Scheme') so that the Directors of the Company will
have more flexibility in determining the price at which options can be
exercised. The Directors believe that it is essential to conserve cash during
the build-up of the Company's business and recognise that its ability to achieve
this will be heavily influenced by retaining and incentivising its highly
skilled scientists and key employees with the availability of options to
subscribe for shares in the Company on attractive terms. Currently the price at
which options can be exercised under the Scheme cannot be less than the market
price on the day before the date of grant which is a significantly restricting
limitation.
Accordingly, it is proposed that the Rules of the Scheme be amended to allow the
Directors to grant options to employees at an exercise price to be determined at
the sole discretion of the Board of Directors. An ordinary resolution to approve
the proposed change will be put to the Annual General Meeting of the Company in
June.


Outlook

2004 has so far been a year of delivering solid progress. We have announced
very beneficial agreements with a number of leading international pharmaceutical
companies including Roche, ALTANA, Solvay and AstraZeneca. We have focused on
creating a quicker and more competitive solution for the drug discovery process
with our accumulated data, which in turn is generating new clients. On behalf
of the Board, I would like to thank everyone who has contributed to Cyprotex's
progress in 2003 - employees, advisors and shareholders. We now have a good
platform for growth and are more able to take advantage of this growing market,
and we look forward to building further on these strong foundations.



Robert Morrisson Atwater
Chairman and Chief Executive Officer
19 April 2004

Chairman & CEO ROBERT MORRISSON ATWATER makes MARKET PURCHASE (THROUGH SIP)of 70,000 ORDINARY SHARES OF 0.1 PENCE EACH in Cyprotex with price per share at 14.50 PENCE (10,000 SHARES)and 14.25 PENCE (60,000 SHARES). Date of transaction 28/04/2004. His total holding following this notification represents 0.06% of issued shares in the company.

IMHO this AGM statement is truly showing the city and investors that the past is in the past with issues of 'The Plumber' and Sheffield University now dead and burried. Cyprotex is clearly showing confidence that Cloe Screen & Cloe PK are excellent products/services and are increasing in demand by the major pharmaceuticals.

Read on :-

Cyprotex PLC
03 June 2004






Press Release 3 June 2004



Cyprotex Plc
('Cyprotex' or 'the Company')

AGM Statement



Cyprotex (LSE: CRX) announces today that, at the Company's Annual General
Meeting, held earlier today, all resolutions before the meeting were duly
passed.



Speaking at the meeting in Swindon, Robert Morrisson Atwater, Chairman and CEO
of Cyprotex plc, said: 'Cyprotex has continued its excellent progress in the
current financial year to date. Central to our progress during this period has
been our continued delivery on contracts won in the current financial year with
a number of well-known pharmaceutical companies. These customers have reported
positive feedback on the Cyprotex product mix not only to us but also to the
industry as a whole leading to a number of new business contracts. As a result,
we are positive that we are on track to achieve 1.9 million of sales by the end
of this financial year and for the Company to continue in its sustained growth.'



- Ends -

For further information:
Cyprotex PLC
Robert Morrisson Atwater, Tel: +44 (0) 1625 505 152

Chairman & Chief Executive Officer
ir@cyprotex.com www.cyprotex.com


Media enquiries:
Bankside
Henry Harrison-Topham / Heather Salmond Tel: +44 (0) 20 7444 4140
henry.ht@bankside.com www.bankside.com


Notes to editors:



Cyprotex PLC - www.cyprotex.com
Cyprotex is a specialist provider of pharmacokinetic information and technology
to evaluate and optimise key properties of potential drugs that determine how
well they will be absorbed, distributed, metabolised and excreted by the body.
This provides pharmaceutical partners with a sound basis for decision-making
regarding compound selection and design that takes into account how the compound
will behave in the body. Cyprotex predicts the likely outcome of administering
either orally or intravenously-administered compounds by modelling human and rat
physiology. Predictions require basic compound information that can be derived
in the laboratory using established methods, all of which are routinely
performed by Cyprotex's experimental capability. This unique combination of
technologies is aimed at improving pharmaceutical productivity by improving the
quality of compound libraries and drug candidates progressing through the drug
pipeline. Cyprotex is based in the UK and is listed on the London Stock
Exchange (CRX).


This information is provided by RNS
The company news service from the London Stock Exchange


This certainly restores my faith as a shareholder that this company is a good long term investment. The share has fallen from 25p in Jan04 to 11.5p and is now very cheap as currently it is at the price it was last Jun03 despite the facts there has been consistent positive news stream coming out of CRX and provisions for exceptionals items (Sheffield Univertsity) had already been made in it's accounts over a year ago!

From a charting and short term TA viewpoint the MACD has generated a buy signal 3 trading days ago and the RSI also generated a strong buy signal as it crossed sharply above it's 10day moving average which lends to indicate MM's are Bullish with a marketable company share to sell to investors.

The AGM statement should do the trick and the share price could easily surge back up to 25p by the time next Interims are expected out on or around 30 Sept, particularly as the statement also indicates several further contract news is fairly imminent.

DYOR and post your comments but IMHO a very positive share to now BUY and will be buying some more to add to my holding.

fully agree with poster and expect with all the news ref agreements etc,the value of these agreements will be in next interims,believe only one way to go and that is up.

Since I last posted on this thread it seems Cyprotex are certainly begining to be making headway.

1st Jul 04 Cyprotex and Peakdale Collaborate in ADME Prediction Technology for More Efficient Drug Discovery

9th Aug 04 Artemis Investment Management Limited holds 7,250,000 shares

20th Sep 04 Interim Report and Accounts for the six months ended 30 June 2004 These are the highlights and worth reading further.

Turnover up by 140% at 886,000 (369,000)
Gross profit 185% higher at 734,000 (257,000)
Pre-tax loss over 22% lower at 832,000 (1.08 million)
Placing of 2.94 million (net of expenses) at beginning of period leaves cash balances at 2.7 million (868,000)
Customer portfolio expanded to 25 major companies including revenue generating contracts with Roche, AstraZeneca, Altana and Solvay
Contractual discussions well advanced with further blue-chip pharmaceutical and biotechnology companies.

8th Oct 04 Serono integrates Cloe Screen and Cloe PK into its drug discovery strategy

12th Oct 04 Director Shareholding

12th Dec 04 Director Shareholding

21st Dec 04 Director Shareholding

And the chart for CRX is now confirming this by showing a rising trend.